WU Lianqiu
Principal Investigator
Wu Lianqiu specializes in the pharmacology of anti-inflammatory and immunity drugs, including the research and development of new drugs and mechanisms of action for immunity and inflammation-related diseases. As project leader, Wu is in charge of many funds.
1. CS-semi5 Inhibits NF-κB Activation to Block Synovial Inflammation, Cartilage Loss and Bone Erosion Associated With Collagen-Induced Arthritis. Front Pharmacol. 2021(12):655101.
2. HLJ2 Effectively Ameliorates Colitis-Associated Cancer via Inhibition of NF-κB and Epithelial-Mesenchymal Transition. Drug Des Devel Ther. 2020(14):4291-4302.
3. Butyric Acid Increases the Therapeutic Effect of EHLJ7 on Ulcerative Colitis by Inhibiting JAK2/STAT3/SOCS1 Signaling Pathway. Front Pharmacol. 2020(10):1553.
4. Colitis Is Effectively Ameliorated by (±)-8-Acetonyl-dihydrocoptisine via the XBP1-NF-κB Pathway. Front Pharmacol. 2017 (8):619-629.
5. Development of an XBP1 Agonist, HLJ2, as a Potential Therapeutic Agent for Ulcerative Colitis. Eur J Pharm Sci. 2017(109): 56-64.
6. Six Scalemic Mixtures of 6-monosubstituted Dihydrobenzophenanthridine Alkaloids from Chelidonium Majus and Optically Active Structures of Enantiomers. Phytochemistry. 2017(144):159-170.
7. The Antinociceptive Effect and Mechanism of Action of SY0916. International Immunopharmacology. 2016(32) :16–23.
8. The Protective Effect of Epicatechin on Experimental Ulcerative Colitis in Mice Is Mediated by Increasing Antioxidation and by the Inhibition of NF-κB pathway. Pharmacol Rep. 2016;68(3):514-520.
9. Synthesis and Structure-Activity Relationships of Quaternary Coptisine Derivatives as Potential Anti-ulcerative Colitis Agents. J Med Chem. 2015; 58(18):7557-71.
